Target intelligence / Profile preview

HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat deep pocket (gp41 NHR pocket)

Target
gp41 NHR pocket
Molecular classification
Viral fusion protein, Type I transmembrane protein, Envelope glycoprotein
01

Overview

The HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat (NHR) deep pocket is a critical structural element involved in the fusion of the HIV-1 viral envelope with the host cell membrane (Chan, D. C., et al., 1997, Cell). During the fusion process, gp41 undergoes a major conformational change where three NHR helices form a central trimeric coiled-coil, and three C-terminal heptad repeat (CHR) helices wrap around them in an antiparallel fashion to form a six-helix bundle (6HB) (Jiang, S., et al., 1993, Nature). The NHR deep pocket is a highly conserved hydrophobic cavity at the base of the NHR coiled-coil that serves as a primary docking site for specific residues within the CHR region (He, Y., et al., 2008, Journal of Biological Chemistry). Because this pocket is essential for 6HB formation and subsequent viral entry, it is a major target for fusion inhibitors, including the FDA-approved peptide Enfuvirtide and second-generation inhibitors like Sifuvirtide and Albuvirtide (Lu, L., et al., 2016, Microbes and Infection). Small molecule inhibitors are also being actively developed to bind this pocket, aiming to disrupt the NHR-CHR interaction and prevent the virus from infecting host CD4+ T-cells (Zhao, Q., et al., 2013, AIDS Reviews).

Other names
gp41 hydrophobic pocketgp41 NHR-CHR interface pocketgp41 fusion pocketgp41 N-terminal heptad repeat (NHR) pocketgp41 coiled-coil cavity
02

Mechanism of action

Fusion inhibition by binding to the NHR coiled-coil pocket, preventing the interaction with the CHR region and subsequent formation of the six-helix bundle required for viral-host membrane fusion.

03

Biological functions

Viral entryMembrane fusionSix-helix bundle (6HB) formationConformational transition
04

Disease associations

HIV-1 infectionAcquired Immunodeficiency Syndrome (AIDS)
05

Safety considerations

Injection site reactions (common with peptide fusion inhibitors)Rapid emergence of drug resistance mutations in the gp41 NHR regionLow oral bioavailability requiring parenteral administrationPotential immunogenicity of synthetic peptide inhibitors
06

Interacting drugs

Enfuvirtide

7 more in the full profile.

07

Biomarkers

HIV-1 RNA viral loadCD4+ T-lymphocyte countgp41 NHR sequence mutations (e.g., G36D, V38A, N43D)

Beyond the preview

Go deeper on HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat deep pocket (gp41 NHR pocket).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat deep pocket (gp41 NHR pocket).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call